Biodegradable Cationic Lipids for Plasma-Stable RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing siRNA or miRNA constructs face susceptibility to nuclease digestion in plasma and their limited ability to gain access to the intracellular compartment where they can bind the protein RISC when administered systemically as the free siRNA or miRNA delivery agents are susceptible to nuclease digestion and limited ability to gain access to the technical compartment where they can bind the target protein RISC when administered systemically as the free siRNA or miRNA delivery agents are susceptible to nuclease digestion and limited ability to gain access to the intracellular compartment where they can bind the protein RISC.
Innovation Solution
The use of biodegradable cationic lipids and PEG lipids to form nucleic acid-lipid particles that protect the nucleic acid from degradation and clearance in serum, facilitate systemic delivery, and provide intracellular delivery with reduced toxicity by incorporating biodegradable groups into the lipid moiety, resulting in faster metabolism and removal from the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cationic lipids are used to form lipid nanoparticles for nucleic acid delivery, then cellular uptake and intracellular delivery are improved, but toxicity increases and therapeutic index decreases
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing biodegradable linkages (e.g., ester bonds, amide bonds) at specific positions in the lipid molecule. This structural parameter change allows the lipid to be metabolized by cellular enzymes after delivering the nucleic acid payload, thereby reducing cumulative toxicity while maintaining effective cellular uptake during the delivery process.
Solution Approach 2:
The biodegradable cationic lipids function as disposable delivery vehicles that perform their protective and delivery function temporarily, then degrade into harmless metabolites. The lipid nanoparticle is designed to be short-lived in the biological system, degrading after nucleic acid release, which eliminates the persistent toxicity associated with stable cationic lipids while preserving the initial delivery efficacy.
2Object-affected harmful factors
If biodegradable groups are incorporated into the lipid moiety to enable faster metabolism, then toxicity is reduced, but delivery efficiency may be compromised
Solution Approach 1:
The biodegradable groups are strategically positioned in the lipid structure so that degradation occurs only after the nucleic acid has been successfully delivered to the intracellular compartment. The lipid maintains its integrity and delivery function during circulation and cellular uptake, then triggers degradation through enzymatic cleavage of the biodegradable linkage after payload release, ensuring delivery efficiency is not compromised.
Solution Approach 2:
The patent introduces biodegradable characteristics only at specific local positions within the lipid molecule (e.g., at the acyl chain linkage to the headgroup) while maintaining the overall cationic character and membrane-interaction properties of the lipid. This localized modification ensures that the lipid remains effective for delivery while becoming metabolizable after function is completed.
3Reliability
If lipid nanoparticles are used to protect nucleic acid from nuclease digestion, then stability in plasma is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent employs composite lipid nanoparticles composed of biodegradable cationic lipids combined with neutral lipids (such as cholesterol or phospholipids) and PEGylated lipids. This composite structure provides robust protection against nuclease digestion through the formation of a stable lipid shell around the nucleic acid, while the biodegradable cationic component ensures eventual metabolic clearance, balancing protection with reduced system complexity compared to non-biodegradable alternatives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable lipids enhance the delivery of nucleic acids by providing high drug:lipid ratios, protecting against degradation, ensuring systemic delivery, and reducing toxicity, thus improving therapeutic efficacy.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids with other lipid components, such as cholesterol and PEG lipids, and oligonucleotides (such as siRNA and miRNA) have been used to facilitate the cellular uptake of the oligonucleotides
Implementation Method 2
The incorporation of the biodegradable group(s) into the lipid results in faster metabolism and removal of the lipid from the body following delivery of the active agent to a target area
Data Source
AI summary
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.